IP Library › Granted Patent US 12,304,948
Granted Patent B2
US 12,304,948 · App. 18/071,057 · Granted May 20, 2025

Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia

Inventors: Mark I. Greene (Penn Valley, PA); Zheng Cai (Wynnewood, PA); Zhiqiang Zhu (Philadelphia, PA); Douglas B. Cines (Wynnewood, PA)
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
C07K16/24A61K31/702A61K31/727C12N15/85A61K38/00A61K39/39533C07K2317/24C07K2317/31C07K2317/54C07K2317/55C07K2317/565C07K2317/569C07K2317/622C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,304,948
App. No.
18/071,057
Granted
May 20, 2025
Kind
B2
Abstract

Provided herein are isolated antibodies or antibody fragments thereof that immunospecifically bind to platelet factor 4 (PF4). In some embodiments the isolated antibodies or antigen-binding fragments thereof comprise a light chain CDR and framework region comprising SEQ ID NO: 4 and a heavy chain CDR and framework region comprising SEQ ID NO: 10. Also provided herein are methods for treating heparin-induced thrombocytopenia (HIT) and methods for reducing the likelihood that subject will become afflicted with HIT. Further disclosed are uses of the isolated antibodies or antibody fragments in the treatment of HIT or the manufacture of compositions for the treatment of HIT.

Claims (18)

1. A polynucleotide encoding a light chain of an antibody, or antigen-binding fragment thereof, that immunospecifically binds to platelet factor 4 (PF4), wherein the light chain or antigen-binding fragment thereof comprises a light chain CDR and framework region comprising the amino acid sequence of SEQ ID NO: 4.

2. The polynucleotide of claim 1 , wherein the light chain or antigen-binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 6.

3. An expression vector comprising the polynucleotide of claim 2 .

4. The polynucleotide of claim 1 , wherein the light chain or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5.

5. An expression vector comprising the polynucleotide of claim 4 .

6. A host cell comprising the expression vector of claim 5 .

7. The host cell of claim 6 , wherein the host cell is a eukaryotic cell, a yeast cell, a plant cell or a bacterium.

8. The host cell of claim 7 , wherein the eukaryotic cell is a 293T cell or a Chinese Hamster Ovary (CHO) cell.

9. An expression vector comprising the polynucleotide of claim 1 .

10. A polynucleotide encoding a heavy chain of an antibody, or antigen-binding fragment thereof, that immunospecifically binds to platelet factor 4 (PF4), wherein the heavy chain or antigen-binding fragment thereof comprises a heavy chain CDR and framework region comprising the amino acid sequence of SEQ ID NO: 10.

11. The polynucleotide of claim 10 , wherein the heavy chain or antigen-binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 12.

12. An expression vector comprising the polynucleotide of claim 11 .

13. The polynucleotide of claim 10 , wherein the heavy chain or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 11.

14. An expression vector comprising the polynucleotide of claim 13 .

15. A host cell comprising the expression vector of claim 14 .

16. The host cell of claim 15 , wherein the host cell is a eukaryotic cell, a yeast cell, a plant cell or a bacterium.

17. The host cell of claim 16 , wherein the eukaryotic cell is a 293T cell or a Chinese Hamster ovary (CHO) cell.

18. An expression vector comprising the polynucleotide of claim 10 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2022
From: GREENE, MARK I.; CAI, ZHENG; ZHU, ZHIQIANG; CINES, DOUGLAS B.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 061909/0345 →
Continuity (3)
Continuation 16611613
Provisional Application 62505303 · May 12, 2017
Related Publication 20230265180A1 · Aug 24, 2023
References Cited (24)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5859205A · Adair et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 6964854B1 · Arepally et al. · 2005 [cited by applicant]
US 7728115B2 · Arepally et al. · 2010 [cited by applicant]
US 10371705B2 · Greene et al. · 2019 [cited by applicant]
US 11524999B2 · Greene · 2022 [cited by examiner]
US 20180024140A1 · Greene et al. · 2018 [cited by applicant]
WO 2016073747A1 · 2016 [cited by applicant]
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature, 1975, vol. 256, No. 5517, pp. 495-497. [cited by applicant]
Kozbor et al., “The production of monoclonal antibodies from human lymphocytes”, Immunology Today, 1983, vol. 4, No. 3, pp. 72-79. [cited by applicant]
Marks et al., “By-passing immunization: Human antibodies from V-gene libraries displayed on phage”, J. Mol. Biol., 1991, vol. 222, No. 3, pp. 581-597. [cited by applicant]
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, J. Mol. Biol., 1987, vol. 196, pp. 901-917. [cited by applicant]
Clackson et al., “Making antibody fragments using phage display libraries”, Nature, Aug. 1991, vol. 352, pp. 624-628. [cited by applicant]
Cole et al., In Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 1985, pp. 77-96. [cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse”, Nature, 1986, vol. 321, pp. 522-525. [cited by applicant]
McMahon et al., “Inappropriate documentation of heparin allergy in the medical record because of misdiagnosis of heparin-induced thrombocytopenia: frequency and consequences”, J. Thrombosis and Haemostasis, 2016, vol. 1… [cited by applicant]
Presta, “Antibody engineering”, Curr. Opin. Struct. Biol., 1992, vol. 2, pp. 593-596. [cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy”, Nature, 1988, vol. 332, pp. 323-327. [cited by applicant]
Udeh et al., “Heparin-induced thrombocytopenia: a clinical and economic review”, OA Anaesthetics, 2013, 1(1):3, 9 pages. [cited by applicant]